TuHURA Q1 expenses rise; Phase 3 MCC trial and Kineta merger on track for Q2 2025

TuHURA Biosciences, Inc./NV

Q1 2025 R&D expenses $4.6M (up 28% YoY); G&A $2.4M (up 140% YoY); shares outstanding ~43.7M.
Initiated Phase 1b/2a trial of IFx-Hu2.0 plus pembrolizumab in first-line Merkel cell carcinoma of unknown primary in May 2025.
Targeting Q2 2025 close of Kineta acquisition; Phase 2 trial of VISTA mAb in NPM1-mutated AML expected Q3 2025.
Phase 3 accelerated approval trial of IFx-Hu2.0 in advanced Merkel cell carcinoma expected to start Q2 2025 after lifting partial clinical hold.
Appointed Dr. Bertrand Le Bourdonnec as EVP Head of Drug Discovery in April 2025; Dr. Craig Tendler joined Board in March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.